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Summary leukemia (Liu et al. 1994; Buchwald et al. 1997). FA
cells are chromosomally unstable and exhibit a marked
Fanconi anemia (FA) is an autosomal recessive chromo-
hypersensitivity to crosslinking agents such as diepoxy-
somal breakage disorder with diverse clinical symptoms
butane, mitomycin C, and cisplatinum, a feature that is
including progressive bone marrow failure and increased
used to assess the FA diagnosis. The crosslinker hyper-
cancer risk. FA cells are hypersensitive to crosslinking
sensitive phenotype has been exploited to assess genetic
agents, which has been exploited to assess genetic het-
heterogeneity through complementation analysis. Using
erogeneity through complementation analysis. Five com-
an Epstein-Barr virus (EBV)–immortalized lymphoblas-
plementation groups (FA-A through FA-E) have so far
toid FA cell line (HSC72) provided with ouabain resis-
been distinguished among the ﬁrst 20 FA patients ana-
tance and hypoxanthine guanine phosphoribosyl trans-
lyzed. Complementation groups in FA are likely to rep-
ferase (HPRT) deficiency as selection markers,
resent distinct disease genes, two of which (FAC and
Duckworth-Rysiecky et al. (1985) carried out cell fu-FAA) have been cloned. Following the identiﬁcation of
sions with unmarked lymphoblast lines from six unre-
the ﬁrst FA-E patient, additional patients were identiﬁed
lated FA patients, resulting in proliferating hybrids that
whose cell lines complemented groups A–D. To assess
survived in selective medium. Three hybrids continuedtheir possible assignment to the E group, we introduced
to show crosslinker hypersensitivity and were thus as-selection markers into the original FA-E cell line and
signed to complementation group A, deﬁned by theiranalyzed fusion hybrids with three cell lines classiﬁed as
functional identity with the fusion partner HSC72. Thenon-ABCD. All hybrids were complemented for cross-
remaining three hybrids had a normal crosslinker sensi-linker sensitivity, indicating nonidentity with group E.
tivity and were thus assigned to (a) group(s) differentWe then marked the three non-ABCDE cell lines and
from A (then termed ‘‘B’’) (Duckworth-Rysiecki et al.examined all possible hybrid combinations for comple-
1985). Subsequent cell-fusion studies using geneticallymentation, which indicated that each individual cell line
marked derivatives of the three non-A cell lines revealedrepresented a separate complementation group. These
that each cell line represented a separate complementa-results thus deﬁne three new groups, FA-F, FA-G, and
tion group, termed ‘‘B,’’ ‘‘C,’’ and ‘‘D,’’ thus totalingFA-H, providing evidence for a minimum of eight dis-
four groups (Strathdee et al. 1992a). Among 13 addi-tinct FA genes.
tional patients subsequently analyzed one patient’s cell
line complemented groups A–D and thus represented a
Introduction ﬁfth group, FA-E (Joenje et al. 1995). Complementation
groups in FA are likely to represent distinct disease genesFanconi anemia (FA) is a rare autosomal recessive dis-
(Buchwald 1995), since the genes for two groups (FACease with variable clinical symptoms including skeletal
and FAA) have been cloned and mapped to chromo-and renal abnormalities, microcephaly, and skin pig-
somes 9q3.22 and 16q24.3, respectively (Strathdee etmentation abnormalities. Patients suffer from a progres-
al. 1992a, 1992b; Pronk et al. 1995; Lo Ten Foe etsive bone marrow failure (panmyelopathy) and in-
al. 1996; Fanconi Anaemia/Breast Cancer Consortiumcreased cancer risk, predominantly acute myeloid
1996), while FAD has been mapped to chromosome
3p22-26 (Whitney et al. 1995).
Following the identiﬁcation of the ﬁrst FA-E patient,Received May 6, 1997; accepted for publication July 11, 1997.
additional patients were identiﬁed whose cell lines com-Address for correspondence and reprints: Dr. H. Joenje, Department
of Human Genetics, Free University, Van der Boechorststraat 7, plemented groups A–D (Joenje 1996). To assess their
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0002-9297/97/6104-0024$02.00 markers into the original FA-E cell line and three cell
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lines classiﬁed as non-ABCD. The results indicate that Complementation Analysis
each of these three cell lines represents a new comple- Polyethylene glycol–induced cell fusion was carried
mentation group, implying the existence of at least eight out as described by Joenje et al. (1995). In brief, 2 1
complementation groups in FA. 107 lymphoblasts from each fusion partner were mixed,
pelleted, and resuspended in serum-free (SF) medium
and divided into four equal portions, for four parallelPatients, Material, and Methods
fusion experiments. After centrifugation, cell fusion was
induced by gently resuspending the cell pellets in 1 mlPatients and Controls
of a solution containing 50% polyethylene glycol (typeEBV-immortalized cell lines were established from
1000; Merck) in SF medium. After 1 min, 8 ml of SFblood samples, obtained—after informed consent—
medium were added, and after 30 min the cells werefrom ethnically and clinically unselected and unrelated
washed by centrifugation and resuspension in completeFA patients. The FA diagnosis was based on clinical
medium. After 48 h at 37C, selection of hybrids wassymptoms in combination with hypersensitivity to
started by adding medium containing HAT plus G418crosslinking agents, as determined in a standard chro-
(400 mg/ml) (fusions with EUFA130NT) or G418 (400mosomal breakage test. Ancestries of the patients
mg/ml) plus hygromycin (200 mg/ml) (fusions with the Nwhose cell lines were studied were Turkish
and H partners). Successful fusion experiments typically(EUFA130), Dutch (EUFA121), and German
showed outgrowth of hybrids after 2–5 wk of culturing(EUFA143 and EUFA173). The cell line EUFA12 was
in selective medium.from a healthy control (Lo Ten Foe et al. 1996).
Growth Inhibition AssayCell Culture
Crosslinker sensitivity of cell lines and hybrids wasB lymphoblastoid cell lines were obtained by immor-
assessed in a growth inhibition test (Ishida and Buch-talization with EBV following standard procedures. Cul-
wald 1982; Joenje et al. 1995): cultures were initiated atture medium was RPMI1640 supplemented with 1 mM
5 1 104/ml in multiple 5-ml aliquots containing variousglutamine (Gibco BRL), 1 mM sodium pyruvate, and
concentrations of mytomycin C (0–100 nM) and al-10% FCS (Gibco BRL). Selection media contained in
lowed to grow for 3–10 d until the cultures not exposedaddition the antibiotic G418 (400 mg/ml Geneticin;
to MMC had undergone at least three population dou-Gibco BRL), hypoxanthine/aminopterin/thymidine
blings; all parallel cultures were then counted with a(HAT) solution (Gibco BRL), or hygromycin (200 mg/
Coulter counter. Hybrids were grown in the continuousml; Boehringer Mannheim) as indicated.
presence of hybrid-selective medium to which the vari-
ous concentrations of MMC were added.Introduction of Selection Markers
The reference FA-E cell line EUFA130 was provided
Transfectionwith two selection markers generating the universal fu-
Lymphoblasts (EUFA130, -121, -143, and -173) weresion partner EUFA130NT. Resistance to the antibiotic
electroporated with pDR2-based expression plasmidsG418 (N) was generated by transfection with pSV2neo,
containing the coding sequence of FAA or FAC as de-and thioguanine resistance (T) was induced by HPRT
scribed by Kruyt et al. (1996). Cells surviving hygro-mutagenesis as described by Joenje et al. (1995). The
mycin selection were tested for MMC-induced growthHPRTmutation confers sensitivity to growth in medium
inhibition to assess complementation of crosslinker hy-containing HAT; HAT blocks de novo synthesis of pu-
persensitivity (Ishida and Buchwald 1992; Joenje et al.rines and kills HPRT0 cells, which are unable to use the
1995). All transfections were successful, except forsalvage pathway of purine synthesis. HAT sensitivity is
EUFA121, which in the case of the FAA-expressing plas-a recessive trait, whereas G418 resistance is dominant,
mid failed to survive hygromycin selection followingso that fusion hybrids generated from EUFA130NTwith
nine independent transfections.unmarked lymphoblasts could be selected by growth in
medium containing both G418 and HAT (Joenje et al.
Ploidy of Fusion Hybrids1995). From the cell lines EUFA130, EUFA121,
EUFA143, and EUFA173, G418-resistant (N) and hy- Tetraploidy of the selected hybrid cell populations
was checked by counting chromosomes in 20 randomlygromycin-resistant (H) derivatives were constructed by
transfection with pSV2Neo and pSV2hph, respectively, selected metaphases. Of the 61 viable hybrids, 52 had
an average chromosome number between 88 and 93 peras described by Strathdee et al. (1992a). Hybrids be-
tween N and H fusion partners were selected in medium cell; 4 had 83, 84, 84, and 87 per cell, respectively. Only
three hybrids had less than an average of 80 chromo-containing both G418 (400 mg/ml) and hygromycin
(200 mg/ml). somes per cell, that is, 71, 74, and 79. Two hybrids
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(both EUFA121H 1 EUFA121N) had only 46 chromo- tive outgrowth of hybrid cell lines was achieved by cul-
turing in medium containing both G418 and HAT. EU-somes per cell and were excluded from the analysis.
FA130NT cells were fused with the three non-ABCD cell
Authentication of Hybrids and Transfected Cell Lines lines EUFA121, EUFA143, and EUFA173, and selected
To exclude inadvertent mix-ups of cell lines during hybrids were analyzed for complementation by testing
cell culturing, hybrids and transfected cell lines were their sensitivity to MMC-induced growth inhibition. As
authenticated by DNA ﬁngerprinting, by use of the shown in ﬁgure 1, all three hybrid cell lines were comple-
VNTR minisatellite marker D1S80 in addition to the mented for crosslinker sensitivity (IC50 values 30–100
microsatellite markers D4S391, D9S175, D10S561, and nM vs. õ1–3 nM for the single cell lines). These results
D17S579, and comparison of the alleles found with indicated that patients EUFA121, EUFA143, and
those present in the original cell lines. EUFA173 did not belong to group E.
To assess possible heterogeneity within these three
non-ABCDE patients, we prepared two drug-resistantResults and Discussion
derivatives from each cell line, N and H, by transfection
To be able to select for heterokaryotic hybrids re- with the plasmids pSV2neo and pSV2hph, respectively,
sulting from fusions with the reference FA-E cell line thus allowing hybrids to be selected in medium con-
EUFA130 we generated a universal fusion partner, taining both the antibiotic G418 and hygromycin as
EUFA130NT, by genetic marking with both neomycin described by Strathdee et al. (1992a). Similarly marked
resistance (N, conferring resistance to the antibiotic derivatives of the FA-E cell line EUFA130 were included
G418) and HPRT deﬁciency (T, conferring resistance in this study.
to 6-thioguanine and sensitivity to medium containing Table 1 summarizes the results from all the fusion
HAT). After fusion with any unmarked cell line, selec- experiments from which viable hybrids were generated,
involving 16—including all reciprocal—combinations.
As expected, all hybrids combining two differently
marked derivatives of the same cell line (homokaryons)
continued to show crosslinker sensitivity, indicating that
complementation was not an artifactual consequence of
the cell fusion and selection procedure. In contrast, all
heterokaryotic hybrids were complemented, that is, ex-
hibiting IC50 values of §30 nM. Some hybrids (e.g.,
EUFA143N 1 EUFA130H) were even more resistant to
MMC than was the average wild-type or complemented
hybrid cell line; we have no explanation for this phe-
nomenon. Overall, the data indicate that each of the four
cell lines analyzed belongs to a distinct complementation
group.
Transfection experiments further substantiated this
result. As expected, non-ABCD cells successfully trans-
fected with expression plasmids containing cDNAs for
FAC and FAA—known to correct the defect in FA-C
and FA-A cell lines, respectively (Strathdee et al. 1992b;
Lo Ten Foe et al. 1996)—failed to be corrected for
crosslinker hypersensitivity (results not shown; for de-
tails, see Patients, Material, and Methods).
Our results thus indicate the existence of three new
complementation groups in FA: FA-F, FA-G, and FA-H,
represented by patients EUFA121, EUFA143, and
EUFA173, respectively, adding up to a total of eightFigure 1 Complementation of MMC sensitivity in hybrids pre-
complementation groups (table 2). Unlike groups A–D,pared from EUFA130NT (FA-E) cells with EUFA121, EUFA143, and
EUFA173. Growth inhibition was assessed as described in Patients, to which multiple patients have been assigned (Joenje et
Material, and Methods. Curves are shown for EUFA130 (), al. 1995, Joenje 1996), groups E–H are represented by
EUFA130NT (/), EUFA121 (l), EUFA143 (), EUFA173 (), and single patients. However, since ongoing complementa-
the hybrids EUFA130NT 1 EUFA121 (), EUFA130NT1 EUFA143
tion studies have identiﬁed 12 additional patients as be-(), and EUFA130NT1 EUFA173 (). EUFA12 () is from a healthy
ing non-ABCD (Joenje 1996; F. di Summa, A. B. Oostra,control. All hybrids of EUFA130 with EUFA121, -143, and -173 are
complemented, indicating nonidentity with the E group. M. A. Rooimans, H. Joenje, unpublished data), it seems
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Table 1
Complementation Analysis of Four Non-ABCD FA Lymphoblastoid Cell Lines
EUFA130H EUFA121H EUFA143H EUFA173H
(5.6 { 1.5; N Å 5) (1.0 { .6; N Å 4) (1.6 { .9; N Å 3) (2.5 { 1.5; N Å 6)
EUFA130N (2.4 { 1.0; N Å 7) 3.6 { 1.1 (4/24) 61.3 { 8.5 (4/4) 83.8 { 25 (4/4) 73.0 { 19.9 (4/4)
EUFA121N (1.3 { .7; N Å 4) 40.0 { 0 (1/24) 2.5 { 0 (3/12) 90.0 { 14.1 (4/4) 30.0 { 5.0 (3/4)
EUFA143N (2.4 { 1.2; N Å 5) 193.0 { 67.5 (4/4) 78.0 { 9.6 (4/4) 3.7 { 1.4 (3/4) 38.8 { 4.8 (4/4)
EUFA173N (1.7 { 1.4; N Å 4) 67.0 { 6.7 (5/15) 57.5 { 11.9 (4/4) 95.0 { 17.3 (4/4) 3.8 { .3 (4/4)
NOTE.—Cell lines, marked with G418-resistance (N) or hygromycin-resistance (H), were fused, and, following selection in medium containing
G418 plus hygromycin, hybrid cell lines were assayed for MMC sensitivity (see Methods). EUFA130 is the reference group E cell line. Numbers
indicate average IC50 values for multiple independently obtained hybrids, { SD (cf. ﬁg. 1). The numbers of successful fusions per total attempted
fusions are indicated in parentheses. Values of IC50 for the parental cell lines, determined in parallel with the relevant hybrids, are indicated
within parentheses. Value of IC50 for the healthy control cell line EUFA12 was 54 { 22 (N Å 17); multiple healthy controls were 47
{ 12 nM, range 32–70 nM (N Å 9).
likely that at least some of these patients are to be as- that FA genes function in a molecular pathway of some
complexity. This pathway is likely to be novel, sincesigned to groups E–H, while others may represent still
new complementation groups. Further cell-fusion stud- the FA gene products identiﬁed to date (FAA and FAC)
have no homologies to any known proteins (D’Andreaies will be necessary to resolve this question.
With the implication of eight separate disease genes 1996). At the clinical level, mutations in FA genes are
associated with developmental abnormalities (typicallyFA has an even higher degree of locus heterogeneity than
xeroderma pigmentosum, with seven complementation affecting the skeleton and kidneys), bone marrow fail-
ure, and increased cancer risk (Buchwald et al. 1997).groups (Hoeijmakers and Bootsma 1994). This hetero-
geneity complicates the molecular diagnosis of FA. The At the cellular level, chromosomal instability, sponta-
neous cell-cycle arrest, and hypersensitivity to cross-fact that certain complementation groups prevail in spe-
ciﬁc populations (FA-C in Ashkenazi Jews [Whitney et linking agents are typically associated with the FA phe-
notype. In addition, recent work has indicated that FAal. 1993; Verlander et al. 1994], FA-A in South African
Afrikaans-speaking people [Pronk et al. 1995] and Ital- cells are more prone to apoptosis than are non-FA cells
(Kruyt et al. 1996; Cumming et al. 1996; Whitney et al.ians [Savoia et al. 1996]) helps to set priorities for muta-
tion screens. On the other hand, all eight complementa- 1996). The relationship between these diverse cellular
functions is unknown, but the FA genes must play antion groups have been found in a sample of 21 FA
patients recruited from a relatively small geographic integrating role. Unlike in xeroderma pigmentosum,
where the implicated genes are known to be intercon-area (Germany and the Netherlands [Joenje 1996]),
which suggests that mutation detection may remain nected through their role in transcription and DNA
repair/replication (Hoeijmakers and Bootsma 1994),cumbersome for a sizable proportion of FA patients
worldwide. the molecular pathology of FA is still elusive and con-
tinues to be a challenge for geneticists and molecularGiven the similar phenotype of FA patients and the
speciﬁc features that characterize FA cells, it is likely biologists (D’Andrea 1996). Whether the functional de-
fect in FA involves FA gene products forming a multi-
protein complex, a reaction sequence, or a combination
of these remains to be elucidated. Identiﬁcation of theTable 2
remaining six or more FA genes should facilitate our
Cell Lines Representing Eight FA Complementation Groups understanding of this disease.
Group Cell Line Reference
FA-A HSC72 Duckworth-Rysiecki et al. (1985) Acknowledgments
FA-B HSC230 Strathdee et al. (1992a)
FA-C HSC536 Strathdee et al. (1992a) We thank Ralf Dietrich (Deutsche FA Hilfe e.V.), Ron Baas
FA-D HSC62 Strathdee et al. (1992a) (Ned. Stichting FA), and Drs. R. Y. J. Tamminga (Groningen),
FA-E EUFA130 Joenje et al. (1995) J. Hermann (Jena), and U. Glo¨ckel (Bamberg), for their help
FA-F EUFA121 Present study in providing blood samples of the FA patients studied, and
FA-G EUFA143 Present study Hans Gille, Leo ten Kate, and Frank Kruyt, for critically read-
FA-H EUFA173 Present study
ing the manuscript. This work was supported by the FA Re-
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search Fund., Eugene, OR, the National Institute of Health p53-independent apoptosis pathway in lymphoblastoid cell
lines. Blood 87:938–948(HL51031), and the Medical Research Council of Canada.
Liu JM, Buchwald M, Walsh CE, Young NS (1994) Fanconi
anemia and novel strategies for therapy. Blood 84:3995–
4007
References Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N,
Wijker M, Parker L, Lightfoot J, et al (1996) ExpressionBuchwald M (1995) Complementation groups: one or more
cloning of a cDNA for the major Fanconi anaemia gene,per gene? Nat Genet 11:228–230
FAA. Nat Genet 14:320–323Buchwald M, Joenje H, Auerbach AD (1997) Fanconi anemia.
Pronk JC, Gibson RA, Savoia A, Wijker M, Morgan NV,In: Vogelstein B, Kinzler KW (eds) Metabolic and molecular
Melchionda S, Ford D, et al (1995) Localisation of the Fan-
basis of inherited disease. McGraw-Hill, New York
coni anaemia complementation group A gene to chromo-
Cumming RC, Liu JM, Youssouﬁan H, Buchwald M (1996) some 16q24.3. Nat Genet 11:338–340
Suppression of apoptosis in hematopoietic factor-dependent Savoia A, Zatterale A, Del Principe D, Joenje H (1996) Fanconi
progenitor cell lines by expression of the FAC gene. Blood anaemia in Italy: high prevalence of complementation group
88:4558–4567 A in two geographic clusters. Hum Genet 97:599–603
D’Andrea AD (1996) Fanconi anaemia forges a novel path- Strathdee CA, Duncan AMV, Buchwald M (1992a) Evidence
way. Nat Genet 14:240–242 for at least 4 Fanconi anaemia genes including FACC on
Duckworth-Rysiecki G, Cornish K, Clarke CA, Buchwald M chromosome 9. Nat Genet 1:196–198
(1985) Identiﬁcation of two complementation groups in Strathdee CA, Gavish H, Shannon WR, Buchwald M (1992b)
Fanconi anaemia. Somat Cell Mol Genet 11:35–41 Cloning of cDNAs for Fanconi’s anaemia by functional
Fanconi Anaemia/Breast Cancer Consortium (1996) Positional complementation. Nature 356:763–767
cloning of the Fanconi anaemia group A gene. Nat Genet Verlander PC, Lin JD, Udono MU, Zhang Q, Gibson RA,
14:324–328 Mathew CG, Auerbach AD (1994) Mutation analysis of the
Hoeijmakers JHJ, Bootsma D (1994) Incisions for excision. Fanconi anaemia gene FACC. Am J Hum Genet 54:595–
Nature 371:654–655 601
Ishida R, Buchwald M (1982) Susceptibility of Fanconi’s anae- Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm MK,
mia lymphoblasts to DNA-crosslinking and alkylating Reifsteck C, Olson S, et al (1996) Germ cell defects and
agents. Cancer Res 42:4000–4006 hematopoietic hypersensitivity to gamma-interferon in mice
Joenje H, Lo Ten Foe JR, Oostra AB, Van Berkel CGM, Rooi- with a targeted disruption of the Fanconi anaemia C gene.
mans MA, Schroeder-Kurth T, Wegner R-D, et al (1995) Blood 88:49–58
Classiﬁcation of Fanconi anaemia patients by complementa- Whitney MA, Saito H, Jakobs PM, Gibson RA, Moses RE,
tion analysis: evidence for a ﬁfth genetic subtype. Blood 86: Grompe M (1993) A common mutation in the FACC gene
2156–2160 causes Fanconi anaemia in Ashkenazi Jews. Nat Genet 4:
Joenje H (for the European Fanconi Anaemia Research Group 202–205
EUFAR) (1996) Fanconi anaemia complementation groups WhitneyMA, ThayerM, Reifsteck C, Olson S, Smith L, Jakobs
in Germany and the Netherlands. Hum Genet 97:280–282 PM, Leach R, et al (1995) Microcell mediated chromosome
Kruyt FAE, Dijkmans LM, Van den Berg TK, Joenje H (1996) transfer maps the Fanconi anemia group D gene to chromo-
some 3p. Nat Genet 11:341–343Fanconi anemia genes act to suppress a crosslinker-inducible
/ 9a38$$oc11 09-15-97 17:29:17 ajhga UC-AJHG
